scholarly journals Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Antonio Ieni ◽  
Giuseppe Angelico ◽  
Valeria Barresi ◽  
Giuseppe Giuffrè ◽  
Francesco Arena ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Her2 Status ◽  
Her2 Overexpression ◽  
Her2 Amplification ◽  
Gastric Carcinomas ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Objectives. A cribriform architectural pattern has been reported in 9% of one unselected consecutively collected series of gastric carcinomas (GC) with unfavourable prognostic outcome. Taking into consideration the biological relevance of the human epidermal growth factor receptor 2 (HER2) status, we have analyzed a cohort of GC with a cribriform component more than 40% (CGC) to evaluate the HER2 amplification rate as a potential target for therapy with trastuzumab. Results. HER2 overexpression was encountered in 21 of 100 (21%) GC; a progressive increase in HER2 amplification was appreciated moving from non-CGC (20.6%) towards CGC cases (21.6%), although this difference does not reach a statistical significance. Nevertheless, either in univariate or in multivariate analyses, stage and HER2 status showed a significant p value (<0.001) in CGC patients. Conclusions. Our data confirmed a worse prognosis in all CGC patients with HER2 amplification, resulting in a shorter survival time. We invite all pathologists in their daily practice to specify the occurrence of cribriform neoplastic component in GC, either in surgical or in bioptical samples, taking into practical assessment the high HER2 overexpression rate in order to correctly treat these patients with worse behavior.

scholarly journals Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Nida Iqbal ◽  
Naveed Iqbal
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Her2 Overexpression ◽  
Breast Cancers ◽  
Her2 Positive ◽  
Therapeutic Implications ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity. Dimerization of the receptor results in the autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptors and initiates a variety of signaling pathways leading to cell proliferation and tumorigenesis. Amplification or overexpression of HER2 occurs in approximately 15–30% of breast cancers and 10–30% of gastric/gastroesophageal cancers and serves as a prognostic and predictive biomarker. HER2 overexpression has also been seen in other cancers like ovary, endometrium, bladder, lung, colon, and head and neck. The introduction of HER2 directed therapies has dramatically influenced the outcome of patients with HER2 positive breast and gastric/gastroesophageal cancers; however, the results have been proved disappointing in other HER2 overexpressing cancers. This review discusses the role of HER2 in various cancers and therapeutic modalities available targeting HER2.

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

2013 ◽  
Vol 31 (21) ◽  
pp. 2692-2698 ◽  
Author(s):  
Ann H. Partridge ◽  
Shari Gelber ◽  
Martine J. Piccart-Gebhart ◽  
Florine Focant ◽  
Matthew Scullion ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Her2 Status ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth ◽  
The Impact ◽  
Positive Breast Cancer

Purpose Previous research has suggested that young age at diagnosis is an independent risk factor for breast cancer recurrence and death. No prior studies have adequately controlled for human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. We sought to evaluate whether age was a prognostic or predictive factor in the HERA trial. Patients and Methods We used 2-year median follow-up data and dichotomized age at 40 years to evaluate its prognostic effect on outcomes for women assigned to trastuzumab for 1 year or observation. Results Of the 1,703 women randomly assigned to 1 year of trastuzumab and 1,698 to observation, 722 (21%) were age ≤ 40 years at study entry. In separate Cox models, controlling for relevant prognostic and predictive factors, disease-free (DFS) and overall survival (OS) hazard ratios (HRs) were consistent for women age ≤ 40 versus > 40 years, regardless of treatment assignment (observation group: DFS HR age ≤ 40 v > 40 years, 1.18; 95% CI, 0.90 to 1.54; OS HR age ≤ 40 v > 40 years, 1.01; 95% CI, 0.60 to 1.69; trastuzumab group: DFS HR age ≤ 40 v > 40 years, 1.11; 95% CI, 0.81 to 1.51; OS HR age ≤ 40 v > 40 years, 1.18; 95% CI, 0.66 to 2.09). Interaction between age group and treatment effect was not statistically significant (DFS P = .89; OS P = .55). Conclusion In a retrospective analysis of a large randomized controlled trial of women with early-stage HER2-positive breast cancer, age was not strongly associated with risk of early recurrence or prediction of benefit from trastuzumab therapy. Future research should investigate whether age is a predictor of later recurrence and evaluate the impact of age within groups with other tumor subtypes.

Incidence of breast cancer among women in the United States, by human epidermal growth factor receptor-2 status: An analysis of National Registry data 2010.

2013 ◽  
Vol 31 (31_suppl) ◽  
pp. 112-112
Author(s):  
Kathy Lang ◽  
Yanni Hao ◽  
Huan Huang ◽  
Victoria Federico ◽  
Joseph Menzin
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Incidence Rates ◽  
Her2 Status ◽  
Newly Diagnosed ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

112 Background: Few studies of breast cancer (BC) incidence by human epidermal growth factor receptor 2 (HER2) status exist as it is not routinely collected in population-based registries. This study used newly collected registry data to evaluate incidence of BC by HER2 status. Methods: The Surveillance, Epidemiology, and End Results (SEER) Program is a system of tumor registries designed to track cancer incidence and survival, covering about 25% of the US population. The SEER*Stat Database used for this analysis provides summary prevalence/incidence rates, frequencies, and case statistics. We evaluated age-adjusted (to the 2000 US population) incidence (number of cases per 100,000 females) of newly diagnosed female BC during 2010, by HER2 status, stratified by age, race, and stage at diagnosis. Cases with unknown values for any stratifier were excluded. Patients were classified as HER2+/HER2- based on a new HER2 status variable collected beginning in 2010. Results: There were 49,347 cases of newly diagnosed female BC in 2010 (7,331 [14.9%] HER2+ and 42,016 [85.1%] HER2-). Annual incidence of HER2+ BC was lower than incidence of HER2- BC (15.5 vs. 87.9 per 100,000 females; p<0.01). Incidence was highest among patients aged 65-74 years (42.4 [HER2+] and 318.1 [HER2-]), followed by 75+ (34.3 and 292.2), 45-64 (33.7 and 170.4) and under 45 (4.8 and 17.5). Incidence rates by race were as follows: Blacks (17.1 [HER2+] and 83.1 [HER2-]), Whites (15.5 and 91.3), Asian or Pacific Islanders (14.9 and 65.5), and American Indian/Alaska Natives (7.3 and 37.1). Incidence rates were highest for less advanced stages of BC: Stage I (6.1 [HER2+], 45.9 [HER2-]), II (5.5, 28.1), III (2.7, 9.9), and IV (1.2, 4.0). Differences in incidence rates across all strata among HER2+ and HER2- patients were statistically significant (p<0.01). Conclusions: This analysis is among the first to utilize the new SEER HER2 status variable. About 15% of newly diagnosed BC cases reported to SEER in 2010 were HER2+. Differences in incidence across age and stage followed a similar pattern for both HER2+ and HER2- BC, while slight differences by race were observed. Further outcomes studies by HER2 status are warranted.

scholarly journals Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)

2014 ◽  
Vol 32 (35) ◽  
pp. 3959-3966 ◽  
Author(s):  
Harold J. Burstein ◽  
Constance T. Cirrincione ◽  
William T. Barry ◽  
Helen K. Chew ◽  
Sara M. Tolaney ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Hormone Receptor ◽  
Growth Factor Receptor ◽  
Her2 Status ◽  
Human Epidermal Growth Factor ◽  
Hormone Receptor Positive ◽  
Epidermal Growth

Purpose CALGB 40302 sought to determine whether lapatinib would improve progression-free survival (PFS) among women with hormone receptor–positive metastatic breast cancer treated with fulvestrant. Patients and Methods Eligible women had estrogen receptor–positive and/or progesterone receptor–positive tumors, regardless of human epidermal growth factor receptor 2 (HER2) status, and prior aromatase inhibitor treatment. Patients received fulvestrant 500 mg intramuscularly on day 1, followed by 250 mg on days 15 and 28 and every 4 weeks thereafter, and either lapatinib 1,500 mg or placebo daily. The study planned to accrue 324 patients and was powered for a 50% improvement in PFS with lapatinib from 5 to 7.5 months. Results At the third planned interim analysis, the futility boundary was crossed, and the data and safety monitoring board recommend study closure, having accrued 295 patients. At the final analysis, there was no difference in PFS (hazard ratio [HR] of placebo to lapatinib, 1.04; 95% CI, 0.82 to 1.33; P = .37); median PFS was 4.7 months for fulvestrant plus lapatinib versus 3.8 months for fulvestrant plus placebo. There was no difference in overall survival (OS) (HR, 0.91; 95% CI, 0.68 to 1.21; P = .25). For HER2-normal tumors, median PFS did not differ by treatment arm (4.1 v 3.8 months). For HER2-positive tumors, lapatinib was associated with longer median PFS (5.9 v 3.3 months), but the differential treatment effect by HER2 status was not significant (P = .53). The most frequent toxicities were diarrhea, fatigue, and rash associated with lapatinib. Conclusion Adding lapatinib to fulvestrant does not improve PFS or OS in advanced ER-positive breast cancer and is more toxic.

scholarly journals Human epidermal growth factor receptor 2 overexpression in gastric and gastroesophageal junction adenocarcinoma in patients seen at the University Teaching Hospital, Lusaka, Zambia

2020 ◽  
Vol 20 (4) ◽  
pp. 1857-64
Author(s):  
Chimwasu Kasochi ◽  
Peter Julius ◽  
Isaac Mweemba ◽  
Violet Kayamba
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Gastroesophageal Junction ◽  
Growth Factor Receptor ◽  
Her2 Overexpression ◽  
Protein Overexpression ◽  
Human Epidermal Growth Factor ◽  
Gastroesophageal Junction Adenocarcinoma ◽  
Epidermal Growth

Background: There are scanty data on the occurrence of gastric tumours overexpressing human epidermal growth factor receptor 2 (HER2) in Africa. Objective: To assess HER2 protein overexpression in gastric and gastroesophageal junction adenocarcinoma (GGEAC) samples from a single centre in Zambia. Methodology: This was a cross-sectional study of formalin-fixed paraffin-embedded blocks with GGEAC. Prepared slides were first stained with Haematoxylin and Eosin and then evaluated for HER2 protein overexpression by immunohistochem- istry. Results: A total of 57 gastric tissues were stained and evaluated for HER2 overexpression. Thirteen (23%) showed overex- pression, 41/57 (72%) had negative and 3/57 (5%) had equivocal staining. The equivocal cases were excluded from the final analysis. Of the remaining 54 tissues, 28 (52%) were from females, and 26 (48%) were from males. The mean age was 59 years (SD 15 years). HER2 overexpression was highest in moderately differentiated tumours (p=0.0005). Intestinal type tu- mours had a higher occurrenc of HER2 overexpression than diffuse or mixed sub-types (p=0.0087). HER2 overexpression was not associated with age (p=0.27), sex (p=1.00) or anatomical location (p=1.00). Conclusion: The occurrence of GGEAC HER2 overexpression in Zambian patients is similar to proportions reported elsewhere, and it is associated with moderately differentiated tumours of the intestinal type. Keywords: Gastric and Gastroesophageal junction adenocarcinoma; Human Epidermal growth factor Receptor 2 over- expression; immunohistochemistry.

Sign in / Sign up

Export Citation Format

Share Document